A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Intravitreal Pharmacokinetics in Mice: SPECT/CT Imaging and Scaling to Rabbits and Humans




TekijätSchmitt M, Hippeläinen E, Ravina M, Arango-Gonzalez B, Antopolsky M, Vellonen KS, Airaksinen AJ, Urtti A

KustantajaAMER CHEMICAL SOC

Julkaisuvuosi2019

JournalMolecular Pharmaceutics

Tietokannassa oleva lehden nimiMOLECULAR PHARMACEUTICS

Lehden akronyymiMOL PHARMACEUT

Vuosikerta16

Numero10

Aloitussivu4399

Lopetussivu4404

Sivujen määrä6

ISSN1543-8384

eISSN1543-8392

DOIhttps://doi.org/10.1021/acs.molpharmaceut.9b00679


Tiivistelmä
Preclinical in vivo tests of retinal drug responses are carried out in mice and rats, often after intravitreal injections. However, quantitative pharmacokinetics in the mouse eye is poorly understood. Ocular pharmacokinetics studies are usually done in rabbits. We investigated elimination of three compounds ([Tc-99m]Tc-pentetate, [In-111]In-pentetreotide, [Tc-99m]Tc-human serum albumin with molecular weights of 510.2 Da, 1506.4 Da, and 66.5 kDa, respectively) from mouse vitreous using imaging with single photon emission computed tomography/computed tomography (SPECT/CT). Increasing molecular weight decreased elimination of the compounds from the mouse eyes. Half-lives of [Tc-99m]Tc-pentetate, [In-111]In-pentetreotide, and [Tc-99m]Tc-human serum albumin in the mouse eyes were 1.8 +/- 0.5 h, 4.3 +/- 1.7 h, and 30.0 +/- 9.0 h, respectively. These values are 3-12-fold shorter than half-lives of similar compounds in the rabbit vitreous. Dose scaling factors were calculated for mouse-to-rabbit and mouse-to-man translation. They were 27-90 and 38-126, respectively, for intravitreal injections in rabbit and man. We show ocular pharmacokinetic parameters for mice and interspecies scaling factors that may augment ocular drug discovery and development.



Last updated on 2024-26-11 at 12:04